Back to today’s briefing

Story perspectives

Sanofi Acquires Vicebio for $1.6 Billion, Boosts Vaccine Portfolio

7/24/2025

45 5

Summary

Story summary

Sanofi SA is set to acquire UK-based Vicebio Ltd. for $1.6 billion, boosting its respiratory virus vaccine portfolio.
The acquisition includes vaccines for RSV and hMPV, along with Vicebio's innovative 'Molecular Clamp' technology.
This technology enables faster development of liquid vaccines, enhancing storage and distribution efficiency.
The deal is anticipated to finalize in Q4 2025, with minimal impact on Sanofi's financial outlook.

1 of 1

Story summary

Sanofi SA is set to acquire UK-based Vicebio Ltd. for $1.6 billion, boosting its respiratory virus vaccine portfolio.
The acquisition includes vaccines for RSV and hMPV, along with Vicebio's innovative 'Molecular Clamp' technology.
This technology enables faster development of liquid vaccines, enhancing storage and distribution efficiency.
The deal is anticipated to finalize in Q4 2025, with minimal impact on Sanofi's financial outlook.